Polaris Venture Management Co. V L.L.C. lowered its position in shares of Trevena Inc. (NASDAQ:TRVN) by 14.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,270,319 shares of the biopharmaceutical company’s stock after selling 398,961 shares during the period. Trevena makes up approximately 15.4% of Polaris Venture Management Co. V L.L.C.’s portfolio, making the stock its 3rd largest position. Polaris Venture Management Co. V L.L.C. owned 4.35% of Trevena worth $14,303,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Wellington Management Group LLP increased its stake in Trevena by 47.0% in the first quarter. Wellington Management Group LLP now owns 5,714,773 shares of the biopharmaceutical company’s stock worth $47,262,000 after buying an additional 1,827,970 shares in the last quarter. Vivo Capital LLC purchased a new stake in Trevena during the first quarter worth $9,924,000. Northpointe Capital LLC increased its stake in Trevena by 92.6% in the second quarter. Northpointe Capital LLC now owns 379,186 shares of the biopharmaceutical company’s stock worth $2,389,000 after buying an additional 182,261 shares in the last quarter. First Manhattan Co. purchased a new stake in Trevena during the second quarter worth $729,000. Finally, Alps Advisors Inc. increased its stake in Trevena by 28.3% in the second quarter. Alps Advisors Inc. now owns 73,294 shares of the biopharmaceutical company’s stock worth $462,000 after buying an additional 16,169 shares in the last quarter. 75.43% of the stock is owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Trevena (NASDAQ:TRVN)

Trevena Inc. (NASDAQ:TRVN) traded down 1.45% during midday trading on Friday, reaching $6.10. The company had a trading volume of 256,953 shares. The stock’s market capitalization is $318.29 million. The company has a 50-day moving average of $6.80 and a 200-day moving average of $7.16. Trevena Inc. has a 12-month low of $5.58 and a 12-month high of $13.02.

Trevena (NASDAQ:TRVN) last released its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by $0.01. Trevena had a negative return on equity of 45.01% and a negative net margin of 841.00%. On average, analysts predict that Trevena Inc. will post ($1.55) EPS for the current fiscal year.

TRVN has been the topic of a number of research analyst reports. Brean Capital restated a “buy” rating and set a $14.00 price target on shares of Trevena in a report on Friday, August 5th. Jefferies Group restated a “buy” rating on shares of Trevena in a report on Friday, August 5th. Zacks Investment Research cut Trevena from a “hold” rating to a “sell” rating in a report on Thursday, October 6th. TheStreet cut Trevena from a “hold” rating to a “sell” rating in a report on Friday, June 17th. Finally, FBR & Co restated a “buy” rating and set a $13.00 price target on shares of Trevena in a report on Thursday, August 4th. Two equities research analysts have rated the stock with a sell rating and nine have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $14.30.

About Trevena

Trevena Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors (GPCRs). Using its product platform, the Company has identified and advanced three differentiated product candidates: Oliceridine (TRV130), TRV027 and TRV250.

5 Day Chart for NASDAQ:TRVN

Receive News & Stock Ratings for Trevena Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc. and related stocks with our FREE daily email newsletter.